Nine prospective studies have now reported on the association between endogenous sex
hormone levels in postmenopausal women and subsequent breast cancer risk (Moore et
al, 1986; Wysowski et al, 1987; Barrett-Connor et al, 1990; Gordon et al, 1990; Garland
et al, 1992; Helzlsouer et al, 1994; Toniolo et al, 1995; Berrino et al, 1996; Dorgan
et al, 1996; Thomas et al, 1997; Zeleniuch-Jacquotte et al, 1997; Hankinson et al,
1998; Cauley et al, 1999; Kabuto et al, 2000). The Endogenous Hormones and Breast
Cancer Collaborative Group (TEHBCCG) conducted a pooled analysis of the original data
of these studies and concluded that both oestrogen and androgen hormones were strongly
associated with risk (TEHBCCG, 2002). Remaining questions include how long prior to
diagnosis the associations between hormone levels and breast cancer are observed and
whether androgens play a part independent of their role as substrates for oestrogen
production. The New York University (NYU) Women's Health Study was one of the first
prospective studies to report a positive association between oestrogens and androgens
and breast cancer risk (Toniolo et al, 1995). We expand here our initial results that
were based on 130 cases for oestrogen analyses and 85 cases for androgen analyses.
The present report includes 297 cases diagnosed between 6 months and 12.7 years after
enrollment in the study. This study has nearly twice as many cases as any previously
published cohort study. Owing to the large sample size and extended follow-up, we
were able to assess the association of breast cancer risk with hormone levels in serum
samples collected five or more years prior to diagnosis. To explore whether the presence
of a growing cancer results in an increase in circulating hormone levels, we also
examined the rate of change per year in hormone and sex-hormone binding globulin (SHBG)
levels in 95 cases and their matched controls who contributed a second blood donation
within 5 years of diagnosis.
MATERIALS AND METHODS
The NYU Women's Health Study cohort
Between 1985 and 1991, the NYU Women's Health Study enrolled 14 275 healthy women
aged 34–65 years at the Guttman Breast Diagnostic Institute, a breast cancer screening
centre in New York City (Toniolo et al, 1991,1995). Women who had been pregnant or
taken hormonal medications in the 6 months preceding their visit were not eligible.
Women were classified as postmenopausal if they reported no menstrual cycles in the
previous 6 months, a total bilateral oophorectomy, or a hysterectomy without total
oophorectomy prior to natural menopause and their age was 52 years or older. A total
of 7054 participants (49.4%) were postmenopausal at the time of initial blood donation.
After written informed consent was obtained, demographic, medical, anthropometric,
reproductive, and dietary data were collected through self-administered questionnaires.
Nonfasting peripheral venous blood (30 ml) was drawn prior to breast examination.
After centrifugation, serum samples were divided into 1 ml aliquots and immediately
stored at −80°C for subsequent biochemical analyses. Up to 1991, women who returned
for annual breast cancer screening were invited to contribute additional blood donations.
Nested case–control study of breast cancer
Breast cancer cases were identified through active follow-up of the cohort by mailed
questionnaires approximately every 2–4 years and telephone interviews for nonrespondents,
as well as record linkage with state cancer registries in New York, New Jersey, and
with the US National Death Index. A capture–recapture analysis estimated the ascertainment
rate in our cohort to be 95% (Kato et al, 1999). Only incident cases (i.e. diagnosed
at least 6 months after blood donation) of invasive breast cancer were included to
avoid selection bias from ‘prevalent’ cases. Medical and pathology reports were requested
to confirm the diagnoses.
For each case, two controls were selected at random from the appropriate risk sets.
The risk set for a case consisted of all women postmenopausal at enrollment who were
alive and free of cancer at the time of diagnosis of the case and who matched the
case on age at entry (±6 months), date of enrollment (±3 months), and number and dates
(±6 months) of subsequent blood donations, if any. Menopausal status was confirmed
by measuring follicle-stimulating hormone (FSH) in all women for whom the lagtime
between last menstrual period and blood donation was less than 2 years and all women
who were less than 60 years old at entry and reported having had a hysterectomy without
complete bilateral oophorectomy and women with FSH levels ⩽12.75 mIU ml−1 were excluded.
Laboratory analyses
All assays were conducted in the Hormones and Cancer Group at the International Agency
for Research on Cancer in Lyon, France. Assays were selected based on the results
of a validity study (Rinaldi et al, 2001). Members of a matched set were always analysed
in the same batch. Oestradiol, oestrone, androstenedione, and FSH were measured by
direct double-antibody radioimmunoassays from DSL (Diagnostic System Laboratories,
TX, USA), testosterone and dehydroepiandrosterone sulphate (DHEAS) were measured by
direct radioimmunoassays from Immunotech (Marseille, France) and SHBG was measured
by a direct ‘sandwich’ immunoradiometric assay (Cis-Bio, Gif-sur-Yvette, France).
The mean intra- and interbatch coefficients of variation were 4.9 and 13.2% respectively
for oestradiol (at a concentration of 257 pmol l−1), 6.7 and 14.4% for oestrone (at
74 pmol l−1), and 7.8 and 13.5% for androstenedione (at 1.4 nmol l−1), 8.7 and 15.8%
for testosterone (at 1.4 nmol l−1), 5.4 and 14.7% for DHEAS (at 1.62 μmol l−1), and
5.6 and 13.5% for SHBG (at 40 nmol l−1).
Statistical methods
The distributions of known risk factors in cases and controls were compared using
the conditional logistic regression model, to take into account the matching (Breslow
and Day, 1980). To test for differences in hormone (and SHBG) levels between case
and control subjects, we used a mixed-effects regression model taking into account
the matched design: after logarithmic transformation to reduce departures from the
normal distribution, the hormone (or SHBG) levels were modelled as a function of a
random stratum effect (matched set) and a fixed effect for case–control status (Cnaan
et al, 1997).
To compute odds ratios (ORs), serum measurements were categorised into quintiles,
using the frequency distribution of the cases and the controls combined. The matched
set data were analysed using conditional logistic regression (Breslow and Day, 1980).
Odds ratios were computed relative to the lowest quintile. Reported trend test P-values
correspond to hormone variables treated as ordered categorical variables. Analyses
were also performed on log-transformed continuous variables. The log2-transformation
was used because it leads to the OR associated with a doubling in hormone level, an
estimate more easily interpretable than those obtained from other logarithmic transformations
(TEHBCCG, 2002). All P-values are two-sided.
To explore whether the presence of a growing cancer results in an increase in circulating
levels of sex hormones, we calculated the rate of change per year in hormone and SHBG
levels in the subset of subjects for whom two blood donations were available and the
second blood donation was within 5 years of the index date. We compared values in
cases and their matched controls using a mixed-effects regression model. These analyses
were controlled for age through the matching. We also controlled for baseline level
of hormone (or SHBG), rate of change per year in body mass index, and time since menopause.
RESULTS
By 1 March 1998, the start date of the latest round of follow-up, 306 participants
postmenopausal at enrollment were first diagnosed with invasive adenocarcinoma of
the breast 6 months or more after entry into the study. Nine cases (3%) were excluded
for the following reasons: postmenopausal status not confirmed by FSH analysis (two
cases), lack of serum (two cases), both selected controls developed cancer (breast
or other) and their serum was reserved for analyses in which they were the index cases
(five cases). The remaining 297 cases are included in the present analysis. Pathology
reports were obtained for 232 cases (78%), and 51 additional cases (16%) were confirmed
by the Tumour Registries. Among the 594 controls initially selected, 31 (5%) were
excluded for the following reasons: postmenopausal status not confirmed by FSH analysis
(four controls), participant had been selected as a control for a previous case (seven
controls), participant developed breast (six controls) or another cancer (14 controls),
and her serum was reserved for analyses in which she was the index case.
Table 1
Table 1
Selected characteristics of study subjects, NYU Women's Health Study, 1985–1998
Case subjects (n=297)
Control subjects (n=563)
Age (years) at enrollment, median (10th–90th percentiles)
60 (54–64)
60 (54–64)
Age (years) at diagnosis, median (10th–90th percentiles)
66.1 (58.5–72.5)
Age (years) at menarche, median (10th–90th percentiles)
12 (11–14)
13 (11–15)
Nulliparous* (%)
77 (30.9%)
117 (23.4%)
Age (years) at first full-term pregnancy, median (10th–90th percentiles)
25 (20 –31)
24.5 (20–30)
Age (years) at menopause, median (10th–90th percentiles)
50 (41–55)
50 (42–55)
First-degree family history of breast cancer
No
234 (78.8%)
445 (79.1%)
Yes, one affected relative ⩾45 years old
43 (14.5%)
93 (16.5%)
Yes, one affected relative <45 years old or more than one affected relative
20 (6.7%)
25 (4.4%)
Prior breast biopsy** (%)
83 (27.9%)
121 (21.5%)
Prior bilateral oophorectomy (%)
47 (15.8%)
78 (13.8%)
Height (cm), median (10th–90th percentiles)
163 (155–170)
162 (152–170)
Weight (kg)***, median (10th–90th percentiles)
68.1 (54.0–84.9)
63.6 (53.6–81.7)
Body mass index (kg m−2)***, median (10th–90th percentiles)
25.7 (21.0–31.4)
24.3 (20.8–30.9)
*
P<0.10,
**
P=0.05,
***
P<0.01.
presents selected characteristics of participants. The median age at enrollment was
60 years (range, 44–65) and the median age at diagnosis was 66.1 years (range, 52.6–77.4).
Compared to controls, the case subjects were characterised by a higher frequency of
nulliparity (31 vs 23%, P=0.09), a higher frequency of history of breast biopsy (28
vs 22%, P=0.05), a higher median weight (68.1 vs 63.6 kg, P=0.002), and higher median
body mass index (25.7 vs 24.3 kg m−2, P=0.007).
Table 2
Table 2
Median (10th and 90th percentiles) serum levels of hormones and SHBG in case and matched
control subjects
Hormone (unit)
Case subjects (n=297)
Control subjects (n=563)
P-valuea
Oestradiol (pmol l−1)
88.86 (57.04–150.40)
81.78 (54.04–137.76)
0.005
Oestrone (pmol l−1)
104.58 (68.46–175.20)
99.03 (60.20–153.51)
<0.001
Testosterone (nmol l−1)
0.87 (0.31–1.89)
0.79 (0.21–1.64)
0.002
Androstenedione (nmol l−1)
2.70 (1.23–5.90)
2.45 (0.96–4.71)
<0.001
DHEAS (μmol l−1)
2.37 (0.92–6.39)
2.13 (0.71–5.07)
0.002
SHBG (nmol l−1)
42.51 (22.1–76.3)
48.11 (24.0–89.6)
<0.001
a
P-values are from the mixed-effects regression model on log2-transformed variables,
controlling for matching factors.
presents descriptive statistics on the hormone and SHBG levels. The median levels
of all oestrogen and androgen hormones were 5% (oestrone) to 10% (DHEAS) higher among
cases than controls. These differences were all highly statistically significant.
SHBG was 13% higher in controls than in cases (P<0.001).
Table 3
Table 3
ORs (95% CI) for breast cancer by quintiles of serum sex hormone and SHBG levels among
postmenopausal women in the NYU Women's Health Study
Quintiles
Hormone
1
2
3
4
5
P for trend
Oestradiol (pmol l
−1
)
Cutpoints
<62.87
62.87–77.18
77.19–92.48
92.49–116.34
>116.34
#cases/#controls
47/123
61/110
52/119
62/108
72/98
Model aa
1.0
1.56 (0.95–2.56)
1.14 (0.69–1.89)
1.63 (0.98–2.71)
2.33 (1.40–3.88)
0.004
Model bb
1.0
1.63 (0.98–2.69)
1.16 (0.69–1.92)
1.69 (1.00–2.84)
2.49 (1.47–4.21)
0.003
Model cc
1.0
1.52 (0.91–2.53)
1.08 (0.64–1.80)
1.50 (0.88–2.55)
2.06 (1.18–3.60)
0.04
Oestrone (pmol l
−1
)
Cutpoints
<74.43
74.43–93.02
93.03–109.93
109.94–133.61
>133.61
#cases/#controls
40/132
64/108
59/113
62/110
72/99
Model aa
1.0
2.26 (1.36–3.78)
2.12 (1.24–3.62)
2.35 (1.38–4.02)
2.97 (1.76–5.02)
<0.001
Model bb
1.0
2.44 (1.43–4.16)
2.30 (1.32–4.00)
2.46 (1.41–4.28)
3.24 (1.87–5.58)
<0.001
Model cc
1.0
2.32 (1.36–3.95)
2.08 (1.18–3.66)
2.15 (1.22–3.80)
2.67 (1.50–4.76)
0.006
Testosterone (nmol l
−1
)
Cutpoints
<0.42
0.42–0.66
0.67–0.94
0.95–1.39
>1.39
#cases/#controls
47/125
60/112
58/114
64/108
68/103
Model aa
1.0
1.63 (0.99–2.68)
1.51 (0.92–2.48)
1.84 (1.11–3.02)
2.15 (1.29–3.59)
0.005
Model bb
1.0
1.69 (1.01–2.81)
1.57 (0.94–2.61)
1.93 (1.16–3.23)
2.37 (1.39–4.04)
0.002
Model cc
1.0
1.64 (0.98–2.74)
1.50 (0.90–2.50)
1.87 (1.12–3.13)
2.05 (1.19–3.53)
0.01
Androstenedione (nmol l
−1
)
Cutpoints
<1.43
1.43–2.16
2.17–2.90
2.91–3.91
>3.91
#cases/#controls
48/123
60/112
54/117
60/111
74/97
Model aa
1.0
1.31 (0.82–2.10)
1.17 (0.73–1.90)
1.44 (0.89–2.33)
2.04 (1.28–3.25)
0.006
Model bb
1.0
1.29 (0.80–2.10)
1.20 (0.74–1.97)
1.45 (0.89–2.37)
2.07 (1.28–3.33)
<0.001
Model cc
1.0
1.24 (0.77–2.03)
1.15 (0.70–1.88)
1.43 (0.87–2.34)
1.89 (1.16–3.07)
<0.001
DHEAS (μmol l
−1
)
Cutpoints
<1.15
1.15–1.83
1.84–2.63
2.64–3.97
>3.97
#cases/#controls
50/120
56/115
56/114
64/107
69/101
Model aa
1.0
1.21 (0.76–1.94)
1.28 (0.79–2.08)
1.53 (0.95–2.47)
1.84 (1.12–3.03)
0.02
Model bb
1.0
1.08 (0.66–1.74)
1.30 (0.80–2.13)
1.44 (0.88–2.34)
1.74 (1.05–2.89)
<0.001
Model cc
1.0
1.08 (0.66–1.75)
1.23 (0.75–2.01)
1.39 (0.85–2.27)
1.61 (0.97–2.69)
<0.001
SHBG (nmol l
−1
)
Cutpoints
<29.70
29.70–40.39
40.40–52.31
52.32–67.85
>67.85
#cases/#controls
74/98
64/108
63/109
49/123
47/125
Model aa
1.0
0.81 (0.52–1.26)
0.73 (0.46–1.17)
0.49 (0.31–0.78)
0.50 (0.31–0.81)
<0.001
Model bb
1.0
0.77 (0.49–1.22)
0.73 (0.45–1.17)
0.46 (0.28–0.75)
0.51 (0.31–0.82)
<0.001
Model cc
1.0
0.82 (0.51–1.30)
0.78 (0.48–1.28)
0.52 (0.31–0.87)
0.58 (0.34–0.98)
0.01
a
Controlling for matching factors only.
b
Adjusting for age at menarche (continuous), family history of breast cancer (no, one
affected first-degree relative >45 years old, one affected first-degree relative <45
years old or more than one affected first-degree relative), parity/age at first birth
(nulliparous, ⩽20 years at first full-term pregnancy, 21–25 years at first full-term
pregnancy, 26–30 years at first full-term pregnancy, >30 years at first full-term
pregnancy), history of total oophorectomy, and history of breast biopsy.
c
Adjusting for all variables in model b, plus body mass index (ln) and height (ln).
presents ORs for breast cancer by quintile of hormone and SHBG levels. Significant
trends of increasing risk with increasing levels of all hormones were observed in
matched analyses not adjusted for additional factors (model a). As body mass index
is a determinant of circulating oestrogen levels (Vermeulen and Verdonck, 1979; Poortman
et al, 1981; Kaye et al, 1991) and therefore on the same causal pathway as oestrogens,
we present adjusted analyses both including and excluding this variable (plus height,
as recommended by Michels et al, 1998). Adjusting for age at menarche, parity, age
at first birth, family history of breast cancer, and history of breast biopsy, one
variable at a time (data not shown) or simultaneously (Table 3, model b) did not materially
affect the ORs. Adjusting for BMI and height (model c) led to a reduction in ORs,
which was more pronounced for oestrogens than for androgens: The top quintile ORs
associated with oestradiol and oestrone were reduced by 17 and 18%, respectively,
whereas for androgens the ORs were reduced by 7–13%. All associations remained strongly
significant. The strongest association with breast cancer was observed for oestrone
with a 3.2-fold increase in risk for women in the highest quintile relative to the
lowest in model b (the corresponding OR was 2.7 in model c). A strong inverse association
was observed with SHBG, with a 49% reduction in risk for women in the top quintile,
as compared to women in the lowest quintile.
Table 4
Table 4
ORs (95% CI) for breast cancer by quintiles of serum sex hormone and SHBG levels among
postmenopausal women in the NYU Women's Health Study with 5 or more years between
blood donation and index date
Quintiles
Hormone
1
2
3
4
5
P for trend
Oestradiol (pmol l
−1
)
Cutpoints
<62.87
62.87–77.18
77.19–92.48
92.49–116.34
>116.34
#cases/#controls
31/75
32/69
35/77
37/77
53/70
Model aa
1.0
1.09 (0.59–2.01)
1.04 (0.58–1.86)
1.08 (0.58–2.00)
2.03 (1.11–3.71)
0.04
Model bb
1.0
1.08 (0.58–2.03)
1.00 (0.55–1.82)
1.13 (0.60–2.13)
2.18 (1.16–4.09)
0.001
Oestrone (pmol l
−1
)
Cutpoints
<74.43
74.43–93.02
93.03–109.93
109.94–133.61
>133.61
#cases/#controls
28/77
45/77
35/79
41/70
42/66
Model aa
1.0
1.78 (0.96–3.30)
1.39 (0.71–2.73)
1.92 (0.99–3.72)
2.07 (1.08–3.96)
0.05
Model bb
1.0
1.90 (1.00–3.60)
1.45 (0.72–2.91)
2.03 (1.02–4.06)
2.28 (1.17–4.47)
0.04
Testosterone (nmol l
−1
)
Cutpoints
<0.42
0.42–0.66
0.67–0.94
0.95–1.39
>1.39
#cases/#controls
36/88
36/75
39/73
41/64
39/68
Model aa
1.0
1.36 (0.75–2.45)
1.45 (0.81–2.61)
1.75 (0.97–3.16)
1.71 (0.93–3.15)
0.06
Model bb
1.0
1.29 (0.70–2.36)
1.44 (0.79–2.63)
1.70 (0.92–3.13)
1.85 (0.99–3.48)
0.02
Androstenedione (nmol l
−1
)
Cutpoints
<1.43
1.43–2.16
2.17–2.90
2.91–3.91
>3.91
#cases/#controls
33/83
42/70
34/72
34/73
47/68
Model aa
1.0
1.49 (0.82–2.69)
1.19 (0.65–2.18)
1.26 (0.68–2.33)
1.81 (1.03–3.19)
0.1
Model bb
1.0
1.47 (0.80–2.69)
1.17 (0.63–2.17)
1.27 (0.68–2.36)
1.88 (1.05–3.35)
0.004
DHEAS (μmol l
−1
)
Cutpoints
<1.15
1.15–1.83
1.84–2.63
2.64–3.97
>3.97
#cases/#controls
33/75
39/76
39/80
37/66
41/66
Model aa
1.0
1.20 (0.68–2.13)
1.19 (0.66–2.13)
1.34 (0.74–2.43)
1.57 (0.84–2.92)
0.18
Model bb
1.0
1.10 (0.61–1.97)
1.15 (0.64–2.08)
1.30 (0.71–2.39)
1.48 (0.78–2.79)
0.19
SHBG (nmol l
−1
)
Cutpoints
<29.70
29.70–40.39
40.40–52.31
52.32–67.85
>67.85
#cases/#controls
45/65
35/80
40/78
36/77
35/69
Model aa
1.0
0.59 (0.33–1.06)
0.67 (0.38–1.19)
0.60 (0.34–1.06)
0.68 (0.38–1.22)
0.25
Model bb
1.0
0.58 (0.32–1.06)
0.68 (0.37–1.22)
0.60 (0.34–1.08)
0.70 (0.39–1.26)
0.31
a
Controlling for matching factors only.
b
Adjusting for age at menarche (continuous), family history of breast cancer (no, one
affected first-degree relative >45 years old, one affected first-degree relative <45 years
old or more than one affected first-degree relative), parity/age at first birth (nulliparous,
⩽20 years at first full-term pregnancy, 21–25 years at first full-term pregnancy,
26–30 years at first full-term pregnancy, >30 years at first full-term pregnancy),
history of total oophorectomy, and history of breast biopsy.
presents ORs from analyses limited to the 191 cases, whose blood was drawn 5 or more
years before diagnosis, and their matched controls. Results were in the same direction
for all the hormones and SHBG as in the analyses including all cases, although the
ORs tended to be closer to unity and the trends were no longer significant for DHEAS
and SHBG.
A second blood sample collected within 5 years of the index date was available for
cases and controls from 95 matched sets. The mean duration between first and second
blood donations was 31 months (s.d., 17.4 months), and the mean duration between second
blood donation and diagnosis was 28 months (s.d., 19.8 months). Table 5
Table 5
Mean rates of change per year in hormone and SHBG levels in 95 cases and 172 matched
controls who had a second preindex date measurement within 5 years of diagnosis
Mean rates of changea per year
Hormone
Crude
Adjustedb
Cases
Controls
P-value
Cases
Controls
P-value
Oestradiol (pmol l−1)
−0.005
−0.015
0.71
0.002
−0.018
0.45
Oestrone (pmol l−1)
0.007
−0.013
0.33
0.008
−0.015
0.28
Testosterone (nmol l−1)
0.045
0.048
0.97
0.069
0.030
0.50
Androstenedione (nmol l−1)
0.080
−0.017
0.09
0.104
−0.034
0.01
DHEAS (μmol l−1)
−0.018
−0.012
0.82
−0.015
−0.012
0.91
SHBG (nmol l−1)
0.001
−0.043
0.14
−0.011
−0.035
0.41
a
Rate of change=[log2 (hormone at second visit)−log2 (hormone at first visit)]/[number
of years between visits].
b
Adjusted for log2 baseline level, rate of change in body mass index and time since
menopause.
reports the mean rates of change per year in hormone and SHBG levels, separately for
cases and controls. For SHBG and all hormones except androstenedione, the mean changes
per year were of very small amplitude and the matched analysis showed no differences
between cases and controls. For androstenedione, the mean rate of change suggested
a slight increase in levels over time (i.e. with decreasing time to diagnosis) among
cases, whereas there was a slight decrease among controls. This marginally statistically
significant difference (P=0.09) became significant after adjusting for baseline androstenedione
level, rate of change in body mass index and time since menopause (P=0.01).
Table 6
Table 6
ORs for breast cancer associated with a doubling in androgen and SHBG levels, with
and without adjustment for oestrogen levels
Adjusted for
Unadjusted
Oestradiol
Oestrone
Testosterone
OR (95% CI)
1.23 (1.08–1.41)
1.17 (1.00–1.36)
1.08 (0.92–1.26)
P-value
0.001
0.04
0.31
Androstenedione
OR (95% CI)
1.33 (1.13–1.57)
1.26 (1.05–1.52)
1.15 (0.95–1.39)
P-value
<0.001
0.01
0.15
DHEAS
OR (95% CI)
1.23 (1.07–1.42)
1.16 (0.99–1.36)
1.06 (0.90–1.26)
P-value
0.004
0.06
0.47
presents the ORs associated with a doubling in androgen levels with and without adjustment
for oestrogen levels. In unadjusted analyses, the ORs varied from 1.23 (testosterone
and DHEAS) to 1.33 (androstenedione) and were all highly statistically significant.
The ORs decreased slightly, but remained statistically significant (or close to, for
DHEAS) after adjustment for oestradiol. The ORs, though, became close to one (1.06–1.15)
and no longer statistically significant after adjustment for oestrone.
DISCUSSION
In 1995, we reported a positive association between endogenous oestrogens and breast
cancer risk based on the first 130 cases observed among the postmenopausal participants
in the NYU Women's Health Study (Toniolo et al, 1995). With an additional 7 years
of follow-up, we confirm our initial results that increasing circulating levels of
oestradiol and oestrone are associated with increasing risk of breast cancer. We also
confirm the positive association with testosterone levels observed previously (Zeleniuch-Jacquotte
et al, 1997). These results are in agreement with those of most published prospective
studies (TEHBCCG, 2002).
Our initial results on total oestradiol and oestrone levels (Toniolo et al, 1995)
were questioned (Kuller, 1995) because measurements were carried out using commercial
radioimmunoassay kits and oestradiol levels were higher than oestrone levels, which
was contrary to expectation in postmenopausal women. To address this criticism, and
prior to performing the assays reported here, we carried out a validity study to assess
various oestrogen and androgen assays (Rinaldi et al, 2001), as recommended by Hankinson
et al (1994). This study allowed us to select direct assays with high intrabatch reproducibility,
high correlation with indirect assays, and accurate ranking of subjects by hormone
serum concentrations. We reassayed all the sera from the previous study using these
methods. In the pooled analysis of nine prospective studies, no differences in endogenous
oestrogen- and androgen-associated relative risks between studies that had used a
method incorporating a purification step and studies that had used a direct, no-extraction
method were found.
Oestrone, with an OR of 3.24 (95% confidence interval (CI)=1.87–5.58; model b) for
women in the top quintile, appeared more strongly associated with risk than oestradiol
(OR=2.49; 95% CI=1.47–4.21). This result is consistent with the results of the pooled
analysis of prospective studies where the OR for women in the top quintile of oestradiol
was 2.00 (95% CI=1.47–2.71) and for women in the top quintiles of oestradiol and oestrone
were 2.19 (95% CI=1.48–3.22), respectively (TEHBCCG, 2002). As oestradiol has greater
potency and binds with oestrogen receptor-α with greater affinity than oestrone (Zava
et al, 1997), a stronger association of risk with oestradiol than with oestrone is
usually expected. Measurement error is not likely to be responsible for our finding
the reverse because the attenuation of the ORs so caused is inversely related to the
reliability of the measurements. In our study, oestrone had a slightly lower reliability
(intraclass correlation coefficient (ICC)=0.58) than oestradiol (ICC=0.66), so that
the ORs observed with oestrone would be expected to be more attenuated than with oestradiol.
New evidence points to a role of oestrogens in the development of breast cancer independent
of oestrogen receptor mediation, through metabolites such as 4- and 16α-hydroxyoestrogens
(Yager, 2000). The stronger association of risk with oestrone than with oestradiol
could therefore result from the higher concentrations of oestrone metabolites, themselves
resulting from the higher concentrations of oestrone than oestradiol observed in postmenopausal
women. Finally, it has been argued that a stronger association would be observed with
the fraction of oestradiol not bound to SHBG, because it is readily available to breast
cells, than with total oestradiol, as we (Toniolo et al, 1995) and others (TEHBCCG,
2002) have previously found. But because we did not measure the various oestrogen
fractions in this study we could not assess this possibility.
Whereas oestrogens are known to directly stimulate breast cell proliferation, it is
not clear whether the role of androgens is only as precursors of oestrogens, or whether
they have a direct role in breast cancer development through conversion into oestrogens
in the breast itself or by direct stimulation of the growth and division of breast
cells. Multivariate analysis, which is mostly used to control for confounding, may
also be used to assess underlying mechanisms (Szklo and Nieto, 1999): If an association
of androgens with breast cancer risk persisted after adjusting for oestrogens, it
would indicate that androgens may act through more direct mechanisms in addition to
increasing oestrogen levels. In our study, the association of androgens with risk
persisted after adjustment for oestradiol, but not after adjustment for oestrone,
the oestrogen that was most strongly associated with risk in these data (Table 6).
These results suggest that the contribution of androgens to breast cancer risk is
largely through their role as substrates for oestrogen production. These analyses,
though, did not take into account the error in measurement resulting from using a
single serum sample to quantify a woman's long-term average hormone levels. We attempted
to correct our estimates for such measurement error (Kim and Zeleniuch-Jacquotte,
1997), using the repeated measurement data from the 317 controls who had contributed
two blood donations. The reliability correlation coefficients estimated from these
data were: 0.66 (95% CI=0.61–0.70) for oestradiol, 0.58 (95% CI=0.53–0.63) for oestrone,
0.63 (95% CI=0.58–0.67) for testosterone, 0.64 (95% CI=0.59–0.68) for androstenedione,
and 0.92 (95% CI=0.91–0.93) for DHEAS, respectively. Our attempts to correct for measurement
error, though, led to uninterpretable results because of the instability in the corrected
estimates resulting from the multicollinearity among hormone variables: among controls,
the Spearman's correlation coefficients for testosterone, androstenedione, and DHEAS
with oestradiol were 0.47, 0.43, and 0.42, respectively, and with oestrone were 0.57,
0.51, and 0.57 respectively.
The oestradiol-adjusted ORs associated with a doubling of androgen levels that we
observed were very similar to those observed in the pooled analysis of prospective
studies (TEHBCCG, 2002), that is, 1.27 for androstenedione (vs 1.26 in our study),
1.15 for DHEAS (vs 1.16), and 1.32 for testosterone (vs 1.17). Oestrone-adjusted ORs
were not presented in that study. Whether the contribution of androgens to breast
cancer risk is direct or indirect, it would be of interest to identify the source
of elevated levels of androgens. The increased DHEAS serum concentrations in women
who develop breast cancer suggest increased adrenal androgen secretion. In a prospective
study including 53 postmenopausal cases, Dorgan et al (2001) assessed the androstenedione : 11β-hydroxyandrostenedione
ratio, which is depressed when the adrenals are the primary source of androstenedione
but elevated when the ovaries are the primary source. They concluded that both the
adrenals and the ovaries appear to contribute to elevated androstenedione levels in
postmenopausal women. Further research on the factors that contribute to elevated
androgen levels is warranted.
The weak association of breast cancer risk with DHEAS that we observed in our initial
analysis (Zeleniuch-Jacquotte et al, 1997) became stronger with the increased sample
size. A substantial association was also observed in several prospective studies and
in the pooled analysis of these studies. The risk for women in the highest quintile
of DHEAS was 60% higher than for women in the lowest quintile. DHEAS can be converted
into DHEA, itself convertible to androstenedione. DHEAS can also be converted into
5-androstenediol, which in postmenopausal women has oestrogenic properties through
binding to oestrogen receptors (Seymour-Munn and Adams, 1983). As pointed out previously,
these results should caution against the use of DHEA as a supplement with various
‘antiageing’ properties (Hankinson et al, 1998). DHEA oral supplementation leads to
significant increases in circulating levels of DHEAS, testosterone, androstenedione,
oestrone, and oestradiol (Genazzani et al, 2001).
Adjusting for body mass index resulted in an attenuation of the ORs associated with
oestrogen levels. These results were expected in the light of the role of adipose
tissue in producing oestrogens in postmenopausal women. Spearman's correlation coefficients
of body mass index with oestradiol and oestrone were 0.39 and 0.34, respectively.
Although smaller, an attenuation of the ORs associated with androgen levels was also
observed. A positive association of obesity with increased levels of testosterone
has been reported (TEHBCCG, 2003). Obesity could therefore contribute to breast cancer
by increasing the amount of androgens available for conversion to oestrogens, in addition
to increasing their rate of conversion. The weak positive correlations between body
mass index and androgen levels that we observed: 0.13, 0.17, and 0.09 with testosterone,
androstenedione, and DHEAS, respectively, are consistent with such an effect.
To further investigate whether elevated levels of sex hormones are involved in the
induction of breast cancer and not simply a byproduct of the tumour, we conducted
an analysis limited to the 191 cases who had donated blood 5 or more years prior to
diagnosis. This analysis showed results in the same directions as overall analyses,
although the tests for trend did not reach statistical significance for DHEAS and
SHBG. Our study is the first to assess the association of breast cancer risk with
circulating levels of sex hormones measured well before diagnosis in a fairly large
group of cases. The results suggest that the observed associations are more likely
due to an effect of circulating hormones on the development of clinical cancer than
to an increase in circulating hormone levels induced by the tumour.
The availability of a second measurement within 5 years of the index date for cases
and controls from 95 matched sets allowed us to examine changes in the levels of hormones
and SHBG prior to the index date. If the elevated levels of hormones observed in case
subjects were due to the presence of tumours, then these levels would be expected
to increase at a faster rate in cases (as they approach diagnosis) than in controls.
The mean rate of change of androstenedione indicated a slight increase in serum levels
in cases but not in controls. However, for all other hormones and SHBG, changes were
of negligible amplitude and not significantly different in cases and controls. These
results suggest that the presence of the growing tumour does not have a major effect
on circulating levels of sex hormones or SHBG.
For completeness and to maximise statistical power, we included in the present analysis
all the case subjects in our previous report if diagnosed after 6 months in the study,
namely, 82 cases (28% of the total) and their controls included in our initial report
were reassayed and included in this report. Excluding these subjects did not materially
affect the results (data not shown).
In conclusion, our results show that the associations between oestrogen and androgen
levels and breast cancer risk are present 5 or more years prior to diagnosis and therefore
more likely represent an effect of circulating hormones than of the tumour. This is
a key finding towards establishing that sex hormones are causally related to breast
cancer. Our results also suggest that the contribution of androgens to breast cancer
risk is largely through their role as substrates for oestrogen production.